Posts

Shutterstock

Elon Musk Excites Psychedelic Industry CEOs with This Tweet

,
This is one of the billionaire's most explicit acknowledgments of the power of psychedelics for mental health applications.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
Ketamine Trial for Alcohol Use Disorder Delivers Very Promising ResultsShutterstock

Ketamine Trial for Alcohol Use Disorder Delivers Very Promising Results

Awakn Life Sciences' Head of Ketamine-Assisted Therapy, Professor Celia Morgan, says world’s first controlled trial to investigate efficacy of ketamine-assisted therapy for treatment of Alcohol Use Disorder "paves the...
Psychedelic Business Spotlight — January 7

Psychedelic Business Spotlight — January 7

,
This week in psychedelic business news: Mindset Pharma partners with global pharmaceutical company; Awakn Life Sciences explores behavioral addictions; Ei.Ventures buys virtual land for psychedelic therapy.

Psychedelic Business Spotlight: November 19

,
This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.

Psychedelic Business Spotlight: October 29

,
This week in psychedelic business news: MindMed's MDMA research pipeline to treat Autism Spectrum Disorder; Cybin EMBARKs; Awakn and MindCure partner to heal alcoholism.
Psychedelic Business Spotlight: September 17, 2021

Psychedelic Business Spotlight: September 17, 2021

,
This week in psychedelic business news: Wesana teams up with MAPS, MindBio Therapeutics announces world-class research and drug development facility, and Awakn Life Sciences buys up ketamine clinics across...
Awakn Life Science CEO Anthony Tennyson "Groundbreaking" MDMA discovery

Awakn Life Sciences CEO Details ‘Groundbreaking’ MDMA Discovery in Quest to Treat Addiction

, ,
Anthony Tennyson tells the Psychedelic Spotlight Podcast that his company has "discovered receptor sites that MDMA interacts with that we believe nobody else in the world knows about."
Awakn Life Sciences Psychedelics

U.K. Psychedelic R&D Company Investigates MDMA, Ketamine for Addiction

Awakn Life Sciences is looking at psychedelics for addiction, namely MDMA and ketamine for alcohol use disorder.